Evotec in €15M extension of research collaboration with Boehringer

Collaboration

Evotec has announced that it has extended its research collaboration with Boehringer Ingelheim for a further 4 years, during which time it will receive research funding, milestones and royalties worth €15 million. This is the third time that the collaboration, initiated in August 2004, has been extended.

At the same time, based on the success to date in central nervous system, inflammation, cardio-metabolic and respiratory diseases, the scope of the collaboration has been expanded to include oncology targets.

Under the terms of the 2004 agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified in the collaboration. In return, Evotec receives research payments, milestones and royalties on any new drugs that reach the market.